[1] LLOVET J M, KELLEY R K, VILLANUEVA A, et al.Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6. [2] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2022 年版)[J/CD]. 肝癌电子杂志, 2022, 9(1): 1-22. [3] ZHU K, CHEN J, LAI L, et al.Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study[J]. Radiology, 2014, 272(1): 284-293. [4] FU Z, LI X, ZHONG J, et al.Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study[J]. Hepatol Int, 2021, 15(3): 663-675. [5] WU J Y, YIN Z Y, BAI Y N, et al.Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study[J]. J Hepatocell Carcinoma, 2021, 8: 1233-1240. |